• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TD Cowen initiated coverage on LENZ Therapeutics with a new price target

    3/18/25 7:53:26 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email
    TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00
    Get the next $LENZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    3/27/2024$28.00Overweight
    Piper Sandler
    More analyst ratings

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

      Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

      4/14/25 8:17:08 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on LENZ Therapeutics with a new price target

      TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

      3/18/25 7:53:26 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on LENZ Therapeutics with a new price target

      Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00

      9/27/24 7:38:17 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care